This Pharmaceutical Giant Just Poured $11B — Time to Buy?
A major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Explore various ways to boost your credit card points effectively. Enhance your earnings and enjoy greater rewards.
18,527 articlesA major pharma player just spent roughly $11 billion to acquire a biotech with a promising eczema drug. This article ...
Sweetgreen faced a rough spell as the market punished sweetgreen that once looked unstoppable. Now, smart investors w...
Finance America widened its lead in June as the top HECM lender, with a 23% market share and 481 endorsements for the...
Starting out in investing can feel overwhelming. This guide breaks down Index Funds vs. ETFs: Which Is Better for Beg...
A new nonprofit, Ethereum Institutional, launches to act as a neutral entry point for institutions exploring Ethereum...
Peter Thiel and Founders Fund have fully exited ETHZilla, dissolving a high-profile treasury bet linked to Ethereum. ...
Retail traders who chased celebrity-backed crypto deals tied to a high-profile political name are confronting losses ...
As of mid-February 2026, state regulators hold a steady advantage in the legal battle over prediction markets, even w...
Ford extended a four-session losing streak after a soft Q2 U.S. sales report, prompting a closer look at rivals GM an...
A growing cohort of self-custody Bitcoin holders now rides a steep unrealized-loss trail, while ETFs trimming exposur...
Microsoft stock has pulled back in a surprising turn for a tech giant. This article unpacks the reasons behind the dr...
Bitcoin hovers in the low-to-mid $60,000s after failing to clear a major resistance zone. With momentum subdued, trad...